2026 Satellite Symposia Schedule
Satellite Symposia will be offered in the following times (subject to review and approval of content).
Tuesday, February 3, 2026, 06:45-07:45
Transforming Ambiguity to Action for Personalized Fabry Care
Sponsored by Amicus Therapeutics
Tuesday, February 3, 2026, 06:45-07:45
The maturation of evidence: what time teaches us about MPS II
Sponsored by Takeda Pharmaceutical Company Limited
Tuesday, February 3, 2026, 12:15-13:15
Evolving Landscape of LDs in Era of Newborn Screening: Monitoring and Treatment Initiation
Sponsored by Sanofi
Tuesday, February 3, 2026, 12:15-13:15
Optimizing lifelong therapy in Fabry disease: navigating complexity and maximizing impact
Sponsored by Takeda Pharmaceutical Company Limited
Tuesday, February 3, 2026, 17:45-18:45
Closing the Loop: From Clinical Management to Patient Experience with Elfabrio® (pegunigalsidase alfa-ivxj)
Sponsored by Chiesi Global Rare Diseases
Tuesday, February 3, 2026, 17:45-18:45
The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience
Sponsored by Azafaros B.V.
Wednesday, February 4, 2026, 06:45-07:45
From Diagnosis to Care: Transforming rare diseases with gene therapies and advanced technologies
Sponsored by Astellas Pharma Inc
Wednesday, February 4, 2026, 06:45-07:45
Shared Mechanisms and Clinical Implications of Secondary GSL Deposition in Lysosomal Disorders
CE Satellite Symposium
Accredited provider: AffinityCE
Jointly Provided by: AffinityCE and Lysosomal & Rare Disorders Research & Treatment Center, Inc (LDRTC)
Wednesday, February 4, 2026, 12:15-13:15
Leveraging Imaging Strategies for Bone Disease in Gaucher Disease: A Case Study Deep Dive
CE Satellite Symposium
Accredited provider: Medical Education Resources (MER)
Jointly Provided by MER and Saterdalen & Associates LLC
Supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Wednesday, February 4, 2026, 12:15-13:15
Optimizing late-onset Pompe disease (LOPD) monitoring in an era of multiple treatment options
Sponsored by Amicus Therapeutics
Wednesday, February 4, 2026, 17:45-18:45
Biomarkers in Gaucher Disease: A Critical Dialogue on Patient Care Evolution Through Clinical Cases
Sponsored Sanofi
Wednesday, February 4, 2026, 17:45-18:45
Rational Design Meets Real-World Relevance: Pegunigalsidase Alfa in the Treatment of Fabry Disease
Sponsored Chiesi Global Rare Diseases
Thursday, February 5, 2026, 06:45-07:45
Homing in on Holistic Management of Late Onset Pompe Disease: Contemporary Insights on Disease Monitoring, Treatment Selection and Switching, and Shared Decision-Making
CE Satellite Symposium
Accredited provider: AKH Inc., Advancing Knowledge in Healthcare
Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC
Supported by an independent educational grant from Amicus Therapeutics, Inc.
Thursday, February 5, 2026, 06:45-07:45
Transforming Patient Care in MPS II
Sponsored by Denali Therapeutics
Thursday, February 5, 2026, 12:15-13:15
Charting a Path in Niemann-Pick Disease Type C: Diagnostic Challenges, Therapeutic Innovations, and Real-World Patient Cases
Sponsored Zevra Therapeutics
Thursday, February 5, 2026, 12:15-13:15
From the Kidney and Beyond: Early, Multi-Organ Impacts in Fabry Disease
Sponsored Sanofi
These Satellite Symposia are not part of the official WORLDSymposium™ program, and WORLDSymposium does not approve or endorse any commercial products or services discussed during the Satellite Symposia or offered for sale by any corporate supporter of the Satellite Symposia. These symposia may or may not offer CE credits; these sessions are not approved for CE through WORLDSymposium.
Eligibility: Registration for WORLDSymposium 2026 and an official name badge are required to attend satellite symposia.